Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Last trade$10.51
Day change+$0.045 (+0.43%)
Day range$10.15 – $11.21
Volume247,015
Market cap$716M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$716.24M
Price / earnings
11.93×
Price / book
2.98×
Price / sales
1.22×
EV / sales
1.56×
EV / EBITDA
8.87×
Profitability
Earnings per share
$0.88
Return on assets
8.92%
Return on equity
24.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.96×
Current ratio
1.68×
Quick ratio
1.16×
Cash ratio
0.19×
Cash flow
Price / cash flow
8.19×
Price / free cash flow
8.43×
Free cash flow
$84.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BVS, quarterly periods
Line item
Q3 FY2026 Sep 26, 2026
Q2 FY2026 Jun 27, 2026
Q1 FY2026 Mar 28, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$142.44M
$153.21M
$132.09M
$157.9M
$138.65M
$147.66M
$123.88M
$153.64M
Cost of revenue
$45.31M
$47.54M
$41.32M
$49.12M
$44.42M
$45.57M
$40.82M
$50.99M
Gross profit
$97.13M
$105.67M
$90.77M
$108.78M
$94.23M
$102.09M
$83.06M
$102.66M
Selling, general and administrative
$82.95M
$82.74M
$78.33M
$82.76M
$78.66M
$79.11M
$73.5M
$86.87M
Research and development
$3.44M
$3.17M
$2.47M
$3.01M
$2.92M
$3.17M
$3.01M
$3.27M
Total operating expenses
$87.43M
$86.54M
$82.35M
$89.3M
$82.98M
$83.72M
$78.11M
$92.21M
Operating income
$9.7M
$19.13M
$8.42M
$19.49M
$11.25M
$18.37M
$4.95M
$10.45M
Interest expense
-$3.76M
-$4.07M
-$4.33M
$0
-$6.18M
-$7.49M
-$7.51M
$0
Income before taxes
$6.16M
$15.31M
$4.52M
$14.14M
$4.67M
$10.31M
-$3.42M
-$53K
Income taxes
-$701K
-$20.9M
$571K
-$3.18M
$664K
$1.04M
-$95K
$550K
Net income
$6.86M
$36.21M
$3.95M
$17.32M
$4.01M
$9.27M
-$3.32M
-$603K
Net income attributable to common shareholders
$5.99M
$36.21M
$3.11M
$14.76M
$3.16M
$9.27M
-$2.64M
-$388K
EBITDA
$20.02M
$29.66M
$20.08M
$33.42M
$22.65M
$30.42M
$16.82M
$22.8M
Basic earnings per share
$0.09
$0.49
$0.05
$0.22
$0.05
$0.11
-$0.04
-$0.01
Diluted earnings per share
$0.08
$0.47
$0.04
$0.20
$0.05
$0.11
-$0.04
-$0.01
Recent news
Company coverage with links to the original publishers.
Bioventus (BVS) reported Q3 2026 earnings of $0.17 per share, matching consensus estimates, but revenues of $142.44 million missed expectations by 4.74%. The stock has gained 79.1% year-to-date, significantly outperforming the S&P 500's 10.7% gain. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. BioCryst Pharmaceuticals (BCRX) is expected to report results on November 4 with anticipated earnings of $0.10 per share, representing 66.7% year-over-year growth.
Bioventus Inc. announced it will report third quarter fiscal year 2026 financial results on November 2, 2026 after market close, with a management conference call at 4:30 p.m. ET to discuss results and provide a business update. The webcast will be available on the company's investor relations website.
Bioventus Inc. announced that Mark Singleton, Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026. The presentation will be webcast live and available for replay on the company's investor website.
Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.
The global orthobiologics market is projected to grow from USD 6.68 billion in 2025 to USD 9.52 billion by 2031, with a CAGR of 6.17%. Growth is driven by rising osteoarthritis cases, sports-related injuries, and advancements in regenerative therapies including stem cell therapy and platelet-rich plasma treatments. North America leads the market while Asia-Pacific is the fastest-growing region.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 26, 2004
$0.61
Mar 31, 2004
unknown
Dec 26, 2003
$0.61
Dec 31, 2003
unknown
Stock splits
Historical share-structure events and their execution dates.